Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Regeneron Pharmaceuticals ( REGN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.5%. By the end of trading, Regeneron Pharmaceuticals fell $4.56 (-2.5%) to $174.84 on light volume. Throughout the day, 612,402 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 867,400 shares. The stock ranged in price between $171.61-$176.41 after having opened the day at $175.85 as compared to the previous trading day's close of $179.40. Other companies within the Health Care sector that declined today were: China Botanic Pharmaceutical ( CBP), down 12.7%, Telik ( TELK), down 11.6%, Given Imaging ( GIVN), down 11.5%, and Stereotaxis ( STXS), down 10.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $16.95 billion and is part of the drugs industry. The company has a P/E ratio of 91.1, above the S&P 500 P/E ratio of 17.7. Shares are up 4.9% year to date as of the close of trading on Monday. Currently there are nine analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Bioline Rx ( BLRX), up 14.7%, Galectin Therapeutics ( GALT), up 14.5%, Aoxing Pharmaceutical Company ( AXN), up 13.6%, and Cormedix ( CRMD), up 11.9%, were all gainers within the health care sector with Humana ( HUM) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

HOLIDAY SPECIAL: Let Jim Cramer show you every trade he is making in his $2.5 Million portfolio. Join now for 14-days FREE. Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round